Current Problems in Surgery
Volume 43, Issue 6 , Pages 391-450 , June 2006

Carcinoid Tumors

  • Chandrajit P. Raut, MD, MSc

      Affiliations

    • Instructor of Surgery, Harvard Medical School, Associate Surgeon, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Matthew H. Kulke, MD

      Affiliations

    • Assistant Professor of Medicine, Harvard Medical School Medical Oncologist, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Jonathan N. Glickman, MD, PhD

      Affiliations

    • Assistant Professor of Pathology, Harvard Medical School, Associate Pathologist, Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Richard S. Swanson, MD

      Affiliations

    • Associate Professor of Surgery, Harvard Medical School, Senior Surgeon, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Stanley W. Ashley, MD

      Affiliations

    • Frank Sawyer Professor of Surgery, Harvard Medical School, Vice Chairman of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts

References 

  1. Lips CJ , Lentjes EG , Hoppener JW . The spectrum of carcinoid tumours and carcinoid syndromes . Ann Clin Biochem . 2003;40(Pt 6):612–627
  2. Lubarsh O . Uber den pimaeren krebs des ileum nebst Bemerkungen ueber das gleichzeitige Vorkommen von krebs und Tuberculos . Virchows Arch . 1888;11:280–317
  3. Ranson WB . Case of primary carcinoma of ileum . Lancet . 1890;2:1020
  4. Oberndorfer S . Karzinoide Rumoren des Dunndarms . Frankf Z Pathol . 1907;1:425–429
  5. Gosset A , Masson P . Tumeurs endocrines de l’appendice . Presse Med . 1914;25:237–239
  6. Masson P . Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of appendicular mucosa . Am J Pathol . 1928;4:181–212
  7. Pearse AG . The APUD cell concept and its implications in pathology . Pathol Annu . 1974;9:27–41
  8. Pearse AG . Neurocristopathy, neuroendocrine pathology and the APUD concept . Z Krebsforsch Klin Onkol Cancer Res Clin Oncol . 1975;84:1–18
  9. Day R , Salzet M . The neuroendocrine phenotype, cellular plasticity, and the search for genetic switches (redefining the diffuse neuroendocrine system) . Neuroendocrinol Lett . 2002;23(5-6):447–451
  10. Williams ED , Sandler M . The classification of carcinoid tum ours . Lancet . 1963;1:238–239
  11. Capella C , Heitz PU , Hofler H , et al.   Revised classification of neuroendocrine tumours of the lung, pancreas and gut . Virchows Arch . 1995;425:547–560
  12. Lu Cortez L , Clemente C , Puig V , Mirada A . [Carcinoid tumor. An analysis of 131 cases] . Rev Clin Esp . 1994;194:291–293
  13. Modlin IM , Sandor A . An analysis of 8305 cases of carcinoid tumors . Cancer . 1997;79:813–829
  14. Newton JN , Swerdlow AJ , dos Santos Silva IM , et al.   The epidemiology of carcinoid tumours in England and Scotland . Br J Cancer . 1994;70:939–942
  15. Soga J . Carcinoids of the rectum (an evaluation of 1271 reported cases) . Surg Today . 1997;27:112–119
  16. Soga J . Carcinoids of the small intestine (a statistical evaluation of 1102 cases collected from the literature) . J Exp Clin Cancer Res . 1997;16:353–363
  17. Woods HF , Bax ND , Ainsworth I . Abdominal carcinoid tumours in Sheffield . Digestion . 1990;45(Suppl 1):17–22
  18. Eriksson B , Oberg K , Skogseid B . Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients . Acta Oncol . 1989;28:373–377
  19. Norheim I , Oberg K , Theodorsson-Norheim E , et al.   Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival . Ann Surg . 1987;206:115–125
  20. Watson RG , Johnston CF , O’Hare MM , et al.   The frequency of gastrointestinal endocrine tumours in a well-defined population—Northern Ireland 1970-1985 . Q J Med . 1989;72(267):647–657
  21. Berge T , Linell F . Carcinoid tumours . Frequency in a defined population during a 12-year period Acta Pathol Microbiol Scand [A] . 1976;84:322–330
  22. Moertel CG , Sauer WG , Dockerty MB , Baggenstoss AH . Life history of the carcinoid tumor of the small intestine . Cancer . 1961;14:901–912
  23. Neary PC , Redmond PH , Houghton T , et al.   Carcinoid disease (review of the literature) . Dis Colon Rectum . 1997;40:349–362
  24. Modlin IM , Lye KD , Kidd M . A 5-decade analysis of 13,715 carcinoid tumors . Cancer . 2003;97:934–959
  25. Godwin JD . Carcinoid tumors. An analysis of 2,837 cases . Cancer . 1975;36:560–569
  26. Travis WD , Rush W , Flieder DB , et al.   Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid . Am J Surg Pathol . 1998;22:934–944
  27. Kulke MH , Mayer RJ . Carcinoid tumors . N Engl J Med . 1999;340:858–868
  28. Jensen RT , Doherty GM . Carcinoid tumors and the carcinoid syndrome . In:  DeVita VTJ ,  Hellman S ,  Rosenberg SA editor. Cancer (Principles and Practice of Oncology) . Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 813–833
  29. Hamilton SR , Aaltonen LA . World Health Organization Classification of Tumors (Pathology and Genetics of Tumors of the Digestive System) . Lyon: IARC Press; 2000;
  30. Soga J , Tazawa K . Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases . Cancer . 1971;28:990–998
  31. Wilander E . Diagnostic pathology of gastrointestinal and pancreatic neuroendocrine tumours . Acta Oncol . 1989;28:363–369
  32. Johnson LA , Lavin PT , Moertel CG , et al.   Carcinoids (the prognostic effect of primary site histologic type variations) . J Surg Oncol . 1986;33:81–83
  33. Kloppel G , Heitz PU . Classification of normal and neoplastic neuroendocrine cells . Ann N Y Acad Sci . 1994;733:19–23
  34. Soga J , Tazawa K , Aizawa O , et al.   Argentaffin cell adenocarcinoma of the stomach (an atypical carcinoid?) . Cancer . 1971;28:999–1003
  35. Moyana TN , Xiang J , Senthilselvan A , Kulaga A . The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids (importance of histologic grading, MIB-1, p53, and bcl-2 immunoreactivity) . Arch Pathol Lab Med . 2000;124:570–576
  36. Caplin ME , Buscombe JR , Hilson AJ , et al.   Carcinoid tumour . Lancet . 1998;352:799–805
  37. Schnirer II , Yao JC , Ajani JA . Carcinoid—a comprehensive review . Acta Oncol . 2003;42:672–692
  38. Feldman JM . Carcinoid tumors and the carcinoid syndrome . Curr Probl Surg . 1989;26:835–885
  39. Creutzfeldt W . Carcinoid tumors (development of our knowledge) . World J Surg . 1996;20:126–131
  40. Dong Q , Debelenko LV , Chandrasekharappa SC , et al.   Loss of heterozygosity at 11q13 (analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1) . J Clin Endocrinol Metab . 1997;82:1416–1420
  41. Jakobovitz O , Nass D , DeMarco L , et al.   Carcinoid tumors frequently display genetic abnormalities involving chromosome 11 . J Clin Endocrinol Metab . 1996;81:3164–3167
  42. Debelenko LV , Brambilla E , Agarwal SK , et al.   Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung . Hum Mol Genet . 1997;6:2285–2290
  43. Perkins P , Lee JR , Kemp BL , Cox JD . Carcinoid tumors of the lung and family history of cancer . J Clin Epidemiol . 1997;50:705–709
  44. Walch AK , Zitzelsberger HF , Aubele MM , et al.   Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization . Am J Pathol . 1998;153:1089–1098
  45. Kytola S , Nord B , Elder EE , et al.   Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas . Genes Chromosomes Cancer . 2002;34:325–332
  46. Lollgen RM , Hessman O , Szabo E , et al.   Chromosome 18 deletions are common events in classical midgut carcinoid tumors . Int J Cancer . 2001;92:812–815
  47. Terris B , Meddeb M , Marchio A , et al.   Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system . Genes Chromosomes Cancer . 1998;22:50–56
  48. Tonnies H , Toliat MR , Ramel C , et al.   Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation . Gut . 2001;48:536–541
  49. Zhao J , de Krijger RR , Meier D , et al.   Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids) (marked differences indicating diversity in molecular pathogenesis) . Am J Pathol . 2000;157:1431–1438
  50. Gortz B , Roth J , Krahenmann A , et al.   Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms . Am J Pathol . 1999;154:429–436
  51. Petzmann S , Ullmann R , Halbwedl I , Popper HH . Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids (an array comparative genomic hybridization-based study) . Virchows Arch . 2004;445:151–159
  52. Coppola D , Clarke M , Landreneau R , et al.   Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung . Mod Pathol . 1996;9:484–490
  53. Brambilla E , Negoescu A , Gazzeri S , et al.   Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors . Am J Pathol . 1996;149:1941–1952
  54. Azzoni C , Doglioni C , Viale G , et al.   Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids . Am J Surg Pathol . 1996;20:433–441
  55. Chaudhry A , Funa K , Oberg K . Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system . Acta Oncol . 1993;32:107–114
  56. Terris B , Scoazec JY , Rubbia L , et al.   Expression of vascular endothelial growth factor in digestive neuroendocrine tumours . Histopathology . 1998;32:133–138
  57. Ambs S , Bennett WP , Merriam WG , et al.   Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53 . Br J Cancer . 1998;78:233–239
  58. Chaudhry A , Oberg K , Gobl A , et al.   Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system . Anticancer Res . 1994;14(5B):2085–2091
  59. Krishnamurthy S , Dayal Y . Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids . Am J Surg Pathol . 1997;21:327–333
  60. Nilsson O , Wangberg B , Kolby L , et al.   Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours . Int J Cancer . 1995;60:645–651
  61. Modlin IM , Tang LH . Cell and tumour biology of the gastric enterochromaffin-like cell . Ital J Gastroenterol Hepatol . 1999;31(Suppl 2):S117–S130
  62. Chaudhry A , Papanicolaou V , Oberg K , et al.   Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system . Cancer Res . 1992;52:1006–1012
  63. Tormey WP , FitzGerald RJ . The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid . Postgrad Med J . 1995;71(839):542–545
  64. Feldman JM , Lee EM . Serotonin content of foods (effect on urinary excretion of 5-hydroxyindoleacetic acid) . Am J Clin Nutr . 1985;42:639–643
  65. Feldman JM , Butler SS , Chapman BA . Interference with measurement of 3-methoxy-4-hydroxymandelic acid and 5-hydroxyindoleacetic acid by reducing metabolites . Clin Chem . 1974;20:607–610
  66. Eriksson B , Oberg K , Stridsberg M . Tumor markers in neuroendocrine tumors . Digestion . 2000;62(Suppl 1):33–38
  67. Janson ET , Holmberg L , Stridsberg M , et al.   Carcinoid tumors (analysis of prognostic factors and survival in 301 patients from a referral center) . Ann Oncol . 1997;8:685–690
  68. Kema IP , de Vries EG , Slooff MJ , et al.   Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors . Clin Chem . 1994;40:86–95
  69. Reubi JC , Kvols LK , Waser B , et al.   Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas . Cancer Res . 1990;50:5969–5977
  70. Krenning EP , Kooij PP , Bakker WH , et al.   Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history . Ann N Y Acad Sci . 1994;733:496–506
  71. Janson ET , Westlin JE , Eriksson B , et al.   [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours (the predictive value for somatostatin analogue treatment) . Eur J Endocrinol . 1994;131:577–581
  72. Lamberts SW , Uitterlinden P , Verschoor L , et al.   Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 . N Engl J Med . 1985;313:1576–1580
  73. Hanson MW , Feldman JM , Blinder RA , et al.   Carcinoid tumors (iodine-131 MIBG scintigraphy) . Radiology . 1989;172:699–703
  74. Eriksson B , Bergstrom M , Lilja A , et al.   Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors . Acta Oncol . 1993;32:189–196
  75. Eriksson B , Bergstrom M , Sundin A , et al.   The role of PET in localization of neuroendocrine and adrenocortical tumors . Ann N Y Acad Sci . 2002;970:159–169
  76. Thompson GB , van Heerden JA , Martin JK , et al.   Carcinoid tumors of the gastrointestinal tract (presentation, management, and prognosis) . Surgery . 1985;98:1054–1063
  77. Strodel WE , Talpos G , Eckhauser F , Thompson N . Surgical therapy for small-bowel carcinoid tumors . Arch Surg . 1983;118:391–397
  78. Brown NK , Smith MP . Neoplastic diathesis of patients with carcinoid. Report of a case with four other neoplasms . Cancer . 1973;32:216–222
  79. Rivadeneira DE , Tuckson WB , Naab T . Increased incidence of second primary malignancy in patients with carcinoid tumors (case report and literature review) . J Natl Med Assoc . 1996;88:310–312
  80. Gerstle JT , Kauffman GL , Koltun WA . The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies . J Am Coll Surg . 1995;180:427–432
  81. Dusmet ME , McKneally MF . Pulmonary and thymic carcinoid tumors . World J Surg . 1996;20:189–195
  82. Okike N , Bernatz PE , Payne WS , et al.   Bronchoplastic procedures in the treatment of carcinoid tumors of the tracheobronchial tree . J Thorac Cardiovasc Surg . 1978;76:281–291
  83. Torre M , Barberis M , Barbieri B , et al.   Typical and atypical bronchial carcinoids . Respir Med . 1989;83:305–308
  84. Vadasz P , Palffy G , Egervary M , Schaff Z . Diagnosis and treatment of bronchial carcinoid tumors (clinical and pathological review of 120 operated patients) . Eur J Cardiothorac Surg . 1993;7:8–11
  85. Dusmet M , McKneally MF . Bronchial and thymic carcinoid tumors (a review) . Digestion . 1994;55(Suppl 3):70–76
  86. Limper AH , Carpenter PC , Scheithauer B , Staats BA . The Cushing syndrome induced by bronchial carcinoid tumors . Ann Intern Med . 1992;117:209–214
  87. Wajchenberg BL , Mendonca BB , Liberman B , et al.   Ectopic adrenocorticotropic hormone syndrome . Endocr Rev . 1994;15:752–787
  88. Carroll DG , Delahunt JW , Teague CA , et al.   Resolution of acromegaly after removal of a bronchial carcinoid shown to secrete growth hormone releasing factor . Aust N Z J Med . 1987;17:63–67
  89. Harpole DH , Feldman JM , Buchanan S , et al.   Bronchial carcinoid tumors (a retrospective analysis of 126 patients) . Ann Thorac Surg . 1992;54:50–54 discussion 54-5
  90. Marty-Ane CH , Costes V , Pujol JL , et al.   Carcinoid tumors of the lung (do atypical features require aggressive management?) . Ann Thorac Surg . 1995;59:78–83
  91. Smolle-Juttner FM , Popper H , Klemen H , et al.   Clinical features and therapy of “typical” and “atypical” bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma) . Eur J Cardiothorac Surg . 1993;7:121–124 discussion 125
  92. Scully RE , Mark EJ , McNeely WF , et al.   Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1997. A 74-year-old man with progressive cough, dyspnea, and pleural thickening . N Engl J Med . 1997;336:1895–1903
  93. Gough DB , Thompson GB , Crotty TB , et al.   Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia . World J Surg . 1994;18:473–479 discussion 479-80
  94. Rindi G , Luinetti O , Cornaggia M , et al.   Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma (a clinicopathologic study) . Gastroenterology . 1993;104:994–1006
  95. Thomas RM , Baybick JH , Elsayed AM , Sobin LH . Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients . Cancer . 1994;73:2053–2058
  96. Moertel CG , Hanley JA . Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome . Cancer Clin Trials . 1979;2:327–334
  97. Sundler F . Pathogenesis and diagnosis of enterochromaffin-like cell tumors . Ann N Y Acad Sci . 1994;733:24–35
  98. DiSario JA , Burt RW , Vargas H , McWhorter WP . Small bowel cancer (epidemiological and clinical characteristics from a population-based registry) . Am J Gastroenterol . 1994;89:699–701
  99. Gabos S , Berkel J , Band P , et al.   Small bowel cancer in western Canada . Int J Epidemiol . 1993;22:198–206
  100. Ross RK , Hartnett NM , Bernstein L , Henderson BE . Epidemiology of adenocarcinomas of the small intestine (is bile a small bowel carcinogen?) . Br J Cancer . 1991;63:143–145
  101. Weiss NS , Yang CP . Incidence of histologic types of cancer of the small intestine . J Natl Cancer Inst . 1987;78:653–656
  102. Modlin IM , Shapiro MD , Kidd M . Carcinoid tumors and fibrosis (an association with no explanation) . Am J Gastroenterol . 2004;99:2466–2478
  103. Akerstrom G , Makridis C , Johansson H . Abdominal surgery in patients with midgut carcinoid tumors . Acta Oncol . 1991;30:547–553
  104. Memon MA , Nelson H . Gastrointestinal carcinoid tumors (current management strategies) . Dis Colon Rectum . 1997;40:1101–1118
  105. Moertel CG , Dockerty MB , Judd ES . Carcinoid tumors of the vermiform appendix . Cancer . 1968;21:270–278
  106. Moertel CG , Weiland LH , Nagorney DM , Dockerty MB . Carcinoid tumor of the appendix (treatment and prognosis) . N Engl J Med . 1987;317:1699–1701
  107. Hwang RF , Robinson EK , Cusack JCJ , Tyler DS . Small-bowel malignancies and carcinoid tumors . In:  Feig BW ,  Berger DH ,  Fuhrman GM editor. The M. D. Anderson Surgical Oncology Handbook . Philadelphia, PA: Lippincott Williams & Wilkins; 2003;p. 193–214
  108. Ponka JL . Carcinoid tumors of the appendix. Report of thirty-five cases . Am J Surg . 1973;126:77–83
  109. Syracuse DC , Perzin KH , Price JB , et al.   Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases . Ann Surg . 1979;190:58–63
  110. Anderson JR , Wilson BG . Carcinoid tumours of the appendix . Br J Surg . 1985;72:545–546
  111. Subbuswamy SG , Gibbs NM , Ross CF , Morson BC . Goblet cell carcinoid of the appendix . Cancer . 1974;34:338–344
  112. Pahlavan PS , Kanthan R . Goblet cell carcinoid of the appendix . World J Surg Oncol . 2005;3:36–46
  113. Rosenberg JM , Welch JP . Carcinoid tumors of the colon. A study of 72 patients . Am J Surg . 1985;149:775–779
  114. Ballantyne GH , Savoca PE , Flannery JT , et al.   Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry . Cancer . 1992;69:2400–2405
  115. Jetmore AB , Ray JE , Gathright JB , et al.   Rectal carcinoids (the most frequent carcinoid tumor) . Dis Colon Rectum . 1992;35:717–725
  116. Naunheim KS , Zeitels J , Kaplan EL , et al.   Rectal carcinoid tumors–treatment and prognosis . Surgery . 1983;94:670–676
  117. Burke M , Shepherd N , Mann CV . Carcinoid tumours of the rectum and anus . Br J Surg . 1987;74:358–361
  118. Koura AN , Giacco GG , Curley SA , et al.   Carcinoid tumors of the rectum (effect of size, histopathology, and surgical treatment on metastasis free survival) . Cancer . 1997;79:1294–1298
  119. Sauven P , Ridge JA , Quan SH , Sigurdson ER . Anorectal carcinoid tumors . Is aggressive surgery warranted? Ann Surg . 1990;211:67–71
  120. Gibril F , Chen YJ , Schrump DS , et al.   Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1 . J Clin Endocrinol Metab . 2003;88:1066–1081
  121. Shigeta H , Taga M , Kurogi K , et al.   Ovarian strumal carcinoid with severe constipation (immunohistochemical and mRNA analyses of peptide YY) . Hum Pathol . 1999;30:242–246
  122. Davis KP , Hartmann LK , Keeney GL , Shapiro H . Primary ovarian carcinoid tumors . Gynecol Oncol . 1996;61:259–265
  123. Robboy SJ , Norris HJ , Scully RE . Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases . Cancer . 1975;36:404–418
  124. Sugimoto E , Lorelius LE , Eriksson B , Oberg K . Midgut carcinoid tumours. CT appearance . Acta Radiol . 1995;36:367–371
  125. Woodard PK , Feldman JM , Paine SS , Baker ME . Midgut carcinoid tumors (CT findings and biochemical profiles) . J Comput Assist Tomogr . 1995;19:400–405
  126. Woodside KJ , Townsend CM , Mark Evers B . Current management of gastrointestinal carcinoid tumors . J Gastrointest Surg . 2004;8:742–756
  127. Dousset B , Saint-Marc O , Pitre J , et al.   Metastatic endocrine tumors (medical treatment, surgical resection, or liver transplantation) . World J Surg . 1996;20:908–914 discussion 914-5
  128. McEntee GP , Nagorney DM , Kvols LK , et al.   Cytoreductive hepatic surgery for neuroendocrine tumors . Surgery . 1990;108:1091–1096
  129. Que FG , Nagorney DM , Batts KP , et al.   Hepatic resection for metastatic neuroendocrine carcinomas . Am J Surg . 1995;169:36–42 discussion 42-3
  130. Le Treut YP , Delpero JR , Dousset B , et al.   Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report . Ann Surg . 1997;225:355–364
  131. Carrasco CH , Charnsangavej C , Ajani J , et al.   The carcinoid syndrome (palliation by hepatic artery embolization) . AJR Am J Roentgenol . 1986;147:149–154
  132. Clouse ME , Perry L , Stuart K , Stokes KR . Hepatic arterial chemoembolization for metastatic neuroendocrine tumors . Digestion . 1994;55(Suppl 3):92–97
  133. Maton PN , Camilleri M , Griffin G , et al.   Role of hepatic arterial embolisation in the carcinoid syndrome . Br Med J (Clin Res Ed) . 1983;287(6397):932–935
  134. Mitty HA , Warner RR , Newman LH , et al.   Control of carcinoid syndrome with hepatic artery embolization . Radiology . 1985;155:623–626
  135. Nobin A , Mansson B , Lunderquist A . Evaluation of temporary liver dearterialization and embolization in patients with metastatic carcinoid tumour . Acta Oncol . 1989;28:419–424
  136. Ruszniewski P , Rougier P , Roche A , et al.   Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients . Cancer . 1993;71:2624–2630
  137. Ajani JA , Carrasco CH , Wallace S . Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy . Ann N Y Acad Sci . 1994;733:479–487
  138. Eriksson BK , Larsson EG , Skogseid BM , et al.   Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors . Cancer . 1998;83:2293–2301
  139. Diaco DS , Hajarizadeh H , Mueller CR , et al.   Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization . Am J Surg . 1995;169:523–528
  140. Diamandidou E , Ajani JA , Yang DJ , et al.   Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors . AJR Am J Roentgenol . 1998;170:339–344
  141. Drougas JG , Anthony LB , Blair TK , et al.   Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors . Am J Surg . 1998;175:408–412
  142. Kim YH , Ajani JA , Carrasco CH , et al.   Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma . Cancer Invest . 1999;17:474–478
  143. Perry LJ , Stuart K , Stokes KR , Clouse ME . Hepatic arterial chemoembolization for metastatic neuroendocrine tumors . Surgery . 1994;116:1111–1116 discussion 1116-7
  144. Therasse E , Breittmayer F , Roche A , et al.   Transcatheter chemoembolization of progressive carcinoid liver metastasis . Radiology . 1993;189:541–547
  145. McDermott EW , Guduric B , Brennan MF . Prognostic variables in patients with gastrointestinal carcinoid tumours . Br J Surg . 1994;81:1007–1009
  146. Scholte AJ . Ein fall von angioma teleangiectaticum cutis mit chronischer endocarditis und malignem dünndarmcarcinoid . Beitr Pathol Anat . 1931;86:440–443
  147. Vinik AI , Thompson N , Eckhauser F , Moattari AR . Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management . Acta Oncol . 1989;28:389–402
  148. Pernow B , Waldenstrom J . Paroxysmal flushing and other symptoms caused by 5-hydroxytryptamine and histamine in patients with malignant tumours . Lancet . 1954;267(6845):951
  149. Soga J , Yakuwa Y , Osaka M . Carcinoid syndrome (a statistical evaluation of 748 reported cases) . J Exp Clin Cancer Res . 1999;18:133–141
  150. Peart WS , Robertson JI . The effect of a serotonin antagonist (UML 491) in carcinoid disease . Lancet . 1961;2:1172–1174
  151. Vinik AI , McLeod MK , Fig LM , et al.   Clinical features, diagnosis, and localization of carcinoid tumors and their management . Gastroenterol Clin North Am . 1989;18:865–896
  152. Biörck G , Axén O , Thorson A . Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency (fatal outcome after angiocardiography) . Am Heart J . 1952;44:143–148
  153. Lundin L , Norheim I , Landelius J , et al.   Carcinoid heart disease (relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities) . Circulation . 1988;77:264–269
  154. Pellikka PA , Tajik AJ , Khandheria BK , et al.   Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients . Circulation . 1993;87:1188–1196
  155. Robiolio PA , Rigolin VH , Wilson JS , et al.   Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography . Circulation . 1995;92:790–795
  156. Connolly HM , Crary JL , McGoon MD , et al.   Valvular heart disease associated with fenfluramine-phentermine . N Engl J Med . 1997;337:581–588
  157. Jick H , Vasilakis C , Weinrauch LA , et al.   A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation . N Engl J Med . 1998;339:719–724
  158. Khan MA , Herzog CA , St Peter JV , et al.   The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs . N Engl J Med . 1998;339:713–718
  159. Weissman NJ , Tighe JF , Gottdiener JS , Gwynne JT  Sustained-Release Dexfenfluramine Study Group . An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo . N Engl J Med . 1998;339:725–732
  160. Connolly HM , Nishimura RA , Smith HC , et al.   Outcome of cardiac surgery for carcinoid heart disease . J Am Coll Cardiol . 1995;25:410–416
  161. Robiolio PA , Rigolin VH , Harrison JK , et al.   Predictors of outcome of tricuspid valve replacement in carcinoid heart disease . Am J Cardiol . 1995;75:485–488
  162. Basson MD , Ahlman H , Wangberg B , Modlin IM . Biology and management of the midgut carcinoid . Am J Surg . 1993;165:288–297
  163. Dery R . Theoretical and clinical considerations in anaesthesia for secreting carcinoid tumors . Can Anaesth Soc J . 1971;18:245–263
  164. Adams S , Baum RP , Hertel A , et al.   Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours (comparison with the expression of the Ki-67 antigen) . Nucl Med Commun . 1998;19:641–647
  165. Reichlin S . Somatostatin (second of two parts) . N Engl J Med . 1983;309:1556–1563
  166. Reichlin S . Somatostatin . N Engl J Med . 1983;309:1495–1501
  167. Schally AV . Oncological applications of somatostatin analogues . Cancer Res . 1988;48(24 Pt 1):6977–6985
  168. Dharmsathaphorn K , Sherwin RS , Cataland S , et al.   Somatostatin inhibits diarrhea in the carcinoid syndrome . Ann Intern Med . 1980;92:68–69
  169. Frolich JC , Bloomgarden ZT , Oates JA , et al.   The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin . N Engl J Med . 1978;299:1055–1057
  170. Vinik A , Moattari AR . Use of somatostatin analog in management of carcinoid syndrome . Dig Dis Sci . 1989;34(3 Suppl):14S–27S
  171. Kvols LK , Moertel CG , O’Connell MJ , et al.   Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue . N Engl J Med . 1986;315:663–666
  172. Tomassetti P , Migliori M , Gullo L . Slow-release lanreotide treatment in endocrine gastrointestinal tumors . Am J Gastroenterol . 1998;93:1468–1471
  173. Rubin J , Ajani J , Schirmer W , et al.   Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome . J Clin Oncol . 1999;17:600–606
  174. Arnold R , Trautmann ME , Creutzfeldt W , et al.   Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours . Gut . 1996;38:430–438
  175. Janson ET , Oberg K . Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon . Acta Oncol . 1993;32:225–229
  176. Kvols LK , Buck M , Moertel CG , et al.   Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995) . Ann Intern Med . 1987;107:162–168
  177. Oberg K , Norheim I , Theodorsson E . Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide . Acta Oncol . 1991;30:503–507
  178. Saltz L , Trochanowski B , Buckley M , et al.   Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors . Cancer . 1993;72:244–248
  179. Tiensuu Janson EM , Ahlstrom H , Andersson T , Oberg KE . Octreotide and interferon alfa (a new combination for the treatment of malignant carcinoid tumours) . Eur J Cancer . 1992;28A:1647–1650
  180. Creutzfeldt W , Bartsch HH , Jacubaschke U , Stockmann F . Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide . Acta Oncol . 1991;30:529–535
  181. Anthony LB , Woltering EA , Espenan GD , et al.   Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies . Semin Nucl Med . 2002;32:123–132
  182. Buscombe JR , Caplin ME , Hilson AJ . Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors . J Nucl Med . 2003;44:1–6
  183. Kwekkeboom DJ , Bakker WH , Kam BL , et al.   Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate . Eur J Nucl Med Mol Imaging . 2003;30:417–422
  184. Kwekkeboom DJ , Teunissen JJ , Bakker WH , et al.   Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors . J Clin Oncol . 2005;23:2754–2762
  185. McCarthy KE , Woltering EA , Espenan GD , et al.   In situ radiotherapy with 111In-pentetreotide (initial observations and future directions) . Cancer J Sci Am . 1998;4:94–102
  186. Meyers MO , Anthony LB , McCarthy KE , et al.   High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor . South Med J . 2000;93:809–811
  187. Paganelli G , Bodei L , Handkiewicz Junak D , et al.   90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies . Biopolymers . 2002;66:393–398
  188. Waldherr C , Pless M , Maecke HR , et al.   The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours (a clinical phase II study) . Ann Oncol . 2001;12:941–945
  189. Waldherr C , Pless M , Maecke HR , et al.   Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC . J Nucl Med . 2002;43:610–616
  190. De Jong M , Valkema R , Jamar F , et al.   Somatostatin receptor-targeted radionuclide therapy of tumors (preclinical and clinical findings) . Semin Nucl Med . 2002;32:133–140
  191. Virgolini I , Britton K , Buscombe J , et al.   In- and Y-DOTA-lanreotide (results and implications of the MAURITIUS trial) . Semin Nucl Med . 2002;32:148–155
  192. Jamar F , Barone R , Mathieu I , et al.   86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)–a phase 1 clinical study (pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion) . Eur J Nucl Med Mol Imaging . 2003;30:510–518
  193. Safford SD , Coleman RE , Gockerman JP , et al.   Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients . Cancer . 2004;101:1987–1993
  194. Sywak MS , Pasieka JL , McEwan A , et al.   131I-Meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors . World J Surg . 2004;28:1157–1162
  195. Frank M , Klose KJ , Wied M , et al.   Combination therapy with octreotide and alpha-interferon (effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors) . Am J Gastroenterol . 1999;94:1381–1387
  196. Jacobsen MB , Hanssen LE , Kolmannskog F , et al.  The Norwegian carcinoid study   Interferon-alpha 2b, with or without prior hepatic artery embolization (clinical response and survival in mid-gut carcinoid patients) . Scand J Gastroenterol . 1995;30:789–796
  197. Moertel CG , Engstrom PF , Schutt AJ . Tamoxifen therapy for metastatic carcinoid tumor (a negative study) . Ann Intern Med . 1984;100:531–532
  198. Moertel CG . Treatment of the carcinoid tumor and the malignant carcinoid syndrome . J Clin Oncol . 1983;1:727–740
  199. Moertel CG , Martin JK , O’Connell MJ . Phase II trials in the malignant carcinoid tumor and the carcinoid syndrome . Proc Am Soc Clin Oncol . 1982;2:169; abstract
  200. Engstrom PF , Lavin PT , Moertel CG , et al.   Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor . J Clin Oncol . 1984;2:1255–1259
  201. van Hazel GA , Rubin J , Moertel CG . Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine . Cancer Treat Rep . 1983;67:583–585
  202. Bukowski RM , Tangen CM , Peterson RF , et al.  A Southwest Oncology Group study   Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid . Cancer . 1994;73:1505–1508
  203. Ritzel U , Leonhardt U , Stockmann F , Ramadori G . Treatment of metastasized midgut carcinoids with dacarbazine . Am J Gastroenterol . 1995;90:627–631
  204. Oberg K , Norheim I , Lundqvist G , Wide L . Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin–alone or in combination with 5-FU . Acta Oncol . 1987;26:429–432
  205. Moertel CG , Rubin J , O’Connell MJ . Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome . Cancer Treat Rep . 1986;70:1459–1460
  206. Saltz L , Lauwers G , Wiseberg J , Kelsen D . A phase II trial of carboplatin in patients with advanced APUD tumors . Cancer . 1993;72:619–622
  207. Kelsen D , Fiore J , Heelan R , et al.   Phase II trial of etoposide in APUD tumors . Cancer Treat Rep . 1987;71:305–307
  208. Kulke MH , Kim H , Stuart K , et al.   A phase II study of docetaxel in patients with metastatic carcinoid tumors . Cancer Invest . 2004;22:353–359
  209. Bukowski RM , Johnson KG , Peterson RF , et al.  A Southwest Oncology Group Study   A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors . Cancer . 1987;60:2891–2895
  210. Oberg K , Norheim I , Alm G . Treatment of malignant carcinoid tumors (a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon) . Eur J Cancer Clin Oncol . 1989;25:1475–1479
  211. Ajani J , Legha S , Karlin J , et al.   Combination chemotherapy of metastatic carcinoid tumors with 5-FU, adriamycin, and cytoxan and 5-FU, adriamycin, mitomycin, and methy CCNU . Proc Am Assoc Cancer Res . 1983;2:124; abstract
  212. Moertel CG , Kvols LK , O’Connell MJ , Rubin J . Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms . Cancer . 1991;68:227–232
  213. Rougier P , Oliveira J , Ducreux M , et al.   Metastatic carcinoid and islet cell tumours of the pancreas (a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin) . Eur J Cancer . 1991;27:1380–1382
  214. Di Bartolomeo M , Bajetta E , Bochicchio AM , et al.   A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group . Ann Oncol . 1995;6:77–79
  215. Ollivier S , Fonck M , Becouarn Y , Brunet R . Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors (a phase II trial) . Am J Clin Oncol . 1998;21:237–240
  216. Ansell SM , Pitot HC , Burch PA , et al.   A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors . Cancer . 2001;91:1543–1548
  217. Kulke MH , Kim H , Clark JW , et al.   A Phase II trial of gemcitabine for metastatic neuroendocrine tumors . Cancer . 2004;101:934–939
  218. Saltz L , Kemeny N , Schwartz G , Kelsen D . A Phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors . Cancer . 1994;74:958–961
  219. Janson ET , Ronnblom L , Ahlstrom H , et al.   Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors (a randomized trial) . Ann Oncol . 1992;3:635–638
  220. Fjallskog ML , Granberg DP , Welin SL , et al.   Treatment with cisplatin and etoposide in patients with neuroendocrine tumors . Cancer . 2001;92:1101–1107
  221. Kulke M , Ryan D , Stuart K , et al.   Thalidomide in patients with metastatic neuroendocrine tumors . Chemotherapy Foundation Symposium XXI (New York) . 2003; abstract
  222. Yao J , Ng C , Hoff P , et al.   Improved progression-free survival and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab (abstract) . J Clin Oncol . 2005;23:309s
  223. Kulke M , Lenz H , Meropol N , et al.   A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors . Proc Am Soc Clin Oncol . 2005;A4008; abstract
  224. Schupak KD , Wallner KE . The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors . Int J Radiat Oncol Biol Phys . 1991;20:489–495
  225. Saltykow S . Uber die Genese der “karzinoiden Tumoren,” sowie der “Adenomyone” des Darmes . Beitr Path Anat U Z Aug Path . 1912;54:559–594
  226. Hamperl H . Uber gutartige bronchialtumoren (cylindrome und carcinoide) . Virchows Arch . 1937;300:46–88
  227. Lembech F . 5-Hydroxytryptamine in carcinoid tumor . Nature . 1953;172:910–911
  228. Thorson A , Biorck G , Bjorkman G , Waldenstrom J . Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome . Am Heart J . 1954;47:795–817
  229. Page IH , Corcoran AC , Udenfriend S , et al.   Argentaffinoma as endocrine tumour . Lancet . 1955;268:198–199
  230. Sutton R , Doran HE , Williams EM , et al.   Surgery for midgut carcinoid . Endocr Relat Cancer . 2003;10:469–481
  231. Eriksson B , Renstrup J , Imam H , Oberg K . High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors (clinical and biological effects) . Ann Oncol . 1997;8:1041–1044
  232. Ruszniewski P , Ducreux M , Chayvialle JA , et al.   Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide (a prospective study in 39 patients) . Gut . 1996;39:279–283
  233. Modlin IM , Cornelius E , Zoghbi SS , et al.   Phase I-II trial of radiolabelled pentetreotide therapy (abstract) . Proc Am Soc Clin Oncol . 1999;18:186a
  234. Oberg K , Norheim I , Lind E , et al.   Treatment of malignant carcinoid tumors with human leukocyte interferon (long-term results) . Cancer Treat Rep . 1986;70:1297–1304
  235. Nobin A , Lindblom A , Mansson B , Sundberg M . Interferon treatment in patients with malignant carcinoids . Acta Oncol . 1989;28:445–449
  236. Valimaki M , Jarvinen H , Salmela P , et al.   Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? . Cancer . 1991;67:547–549
  237. Moertel CG , Rubin J , Kvols LK . Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon . J Clin Oncol . 1989;7:865–868
  238. Hanssen LE , Schrumpf E , Kolbenstvedt AN , et al.   Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization . Scand J Gastroenterol . 1989;24:787–795
  239. Oberg K , Alm G , Magnusson A , et al.   Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b (development of neutralizing interferon antibodies and possible loss of antitumor activity) . J Natl Cancer Inst . 1989;81:531–535
  240. Bartsch HH , Stockmann F , Arnold R , Creutzfeldt W . Treatment of patients with metastatic carcinoid tumors by recombinant human interferon-alpha—results from a phase II study (abstract) . J Cancer Res Clin Oncol . 1990;116(Suppl):305
  241. Oberg K , Eriksson B . The role of interferons in the management of carcinoid tumors . Acta Oncol . 1991;30:519–522
  242. Schober C , Schmoll E , Schmoll HJ , et al.   Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours . Eur J Cancer . 1992;28A:1664–1666
  243. Joensuu H , Kumpulainen E , Grohn P . Treatment of metastatic carcinoid tumour with recombinant interferon alfa . Eur J Cancer . 1992;28A:1650–1653
  244. Biesma B , Willemse PH , Mulder NH , et al.   Recombinant interferon alpha-2b in patients with metastatic apudomas (effect on tumours and tumour markers) . Br J Cancer . 1992;66:850–855
  245. Bajetta E , Zilembo N , Di Bartolomeo M , et al.   Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group . Cancer . 1993;72:3099–3105
  246. Di Bartolomeo M , Bajetta E , Zilembo N , et al.   Treatment of carcinoid syndrome with recombinant interferon alpha-2a . Acta Oncol . 1993;32:235–238
  247. Doberauer C , Niederle N , Kloke O , et al.   [Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon] . Onkologie . 1987;10:340–344
  248. Janson ET , Kauppinen HL , Oberg K . Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial . Acta Oncol . 1993;32:231–233
  249. Janson E , Ahlstrom H , Andersson T , Oberg K . Octreotide and interferon alpha (a new combination for the treatment of malignant carcinoid tumors) . Eur J Cancer . 1992;10:1647–1650
  250. Taal BG , Hoefnagel CA , Valdes Olmos RA , et al.   Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors . J Clin Oncol . 1996;14:1829–1838
  251. Kvols LK . Therapy of the malignant carcinoid syndrome . Endocrinol Metab Clin North Am . 1989;18:557–568

PII: S0011-3840(06)00039-6

doi: 10.1067/j.cpsurg.2006.03.003

Current Problems in Surgery
Volume 43, Issue 6 , Pages 391-450 , June 2006

Article Tools

* Image Usage & Resolution